Evotec SE (SWX:EVT)

Market Cap	871.81M -1.5%
Revenue (ttm)	733.99M -1.1%
Net Income	-96.38M
EPS	-0.54
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	703
Open	n/a
Previous Close	5.01
Day's Range	n/a
52-Week Range	3.85 - 5.82
Beta	n/a
RSI	65.70
Earnings Date	Apr 8, 2026

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and c...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 4,467
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: EVT

Financial Performance

In 2025, Evotec SE's revenue was 788.37 million, a decrease of -1.08% compared to the previous year's 796.97 million. Losses were -103.52 million, -47.21% less than in 2024.

Financial numbers in EUR